Contrasting Item 9 Labs (OTC:INLB) & Straumann (OTCMKTS:SAUHF)

Item 9 Labs (OTC:INLB) and Straumann (OTCMKTS:SAUHF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Earnings & Valuation

This table compares Item 9 Labs and Straumann’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Item 9 Labs $8.12 million 11.07 -$12.27 million N/A N/A
Straumann $1.52 billion 18.88 $97.36 million N/A N/A

Straumann has higher revenue and earnings than Item 9 Labs.

Institutional and Insider Ownership

0.1% of Straumann shares are owned by institutional investors. 19.8% of Item 9 Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Item 9 Labs and Straumann, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Item 9 Labs 0 0 1 0 3.00
Straumann 0 0 0 0 N/A

Item 9 Labs presently has a consensus price target of $4.00, suggesting a potential upside of 316.67%. Given Item 9 Labs’ higher possible upside, equities analysts plainly believe Item 9 Labs is more favorable than Straumann.

Risk & Volatility

Item 9 Labs has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Straumann has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Profitability

This table compares Item 9 Labs and Straumann’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Item 9 Labs -49.00% -12.20% -10.29%
Straumann N/A N/A N/A

Summary

Straumann beats Item 9 Labs on 8 of the 11 factors compared between the two stocks.

About Item 9 Labs

Item 9 Labs Corp. focused on development, manufacturing and distribution of nasal breathing and intra-nasal delivery devices. The Company’s Air Allergy is a discreet personal filter which protects from irritating airborne allergens. Air Sleep/Snore provides drug-free relief for congestion and snoring caused by nasal breathing difficulties. Item 9 Labs Corp., formerly known as Airware Labs Corp, is headquartered in Southern Arizona, United States.

About Straumann

Straumann Holding AG engages in the provision of implant, restorative, and regenerative dentistry solutions to dental professionals and laboratories. It operates through the following segments: Sales Europe, Sales Distributor & Emerging Markets EMEA, Sales NAM, Sales APAC, Sales LATAM, and Operations. The Sales Europe segment comprises of the Group’s premium and Instradent distribution business. The Sales Distributor & Emerging Markets EMEA segment consists of premium and Instradent distribution businesses in Russia, as well as the premium business with European, African, and Middle Eastern distributors. The Sales NAM segment includes ClearCorrect’s clear-aligner business and its associated development and production activities. The Sales APAC involves in the distribution business of Anthogyr implants and prosthetic components in China and the Equinox implants in India. The Sales LATAM segment includes distribution and Instradent businesses in Middle and South America, and Latin America. The Operations segment manufactures plants, implants, and biomaterials. The company was founded by Reinhard Straumann in 1954 and is headquartered in Basel, Switzerland.

Receive News & Ratings for Item 9 Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Item 9 Labs and related companies with MarketBeat.com's FREE daily email newsletter.